IL117564A - Pharmaceutical and diagnostic compositions containing lysine derivatives - Google Patents
Pharmaceutical and diagnostic compositions containing lysine derivativesInfo
- Publication number
- IL117564A IL117564A IL11756496A IL11756496A IL117564A IL 117564 A IL117564 A IL 117564A IL 11756496 A IL11756496 A IL 11756496A IL 11756496 A IL11756496 A IL 11756496A IL 117564 A IL117564 A IL 117564A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical
- compositions containing
- diagnostic compositions
- containing lysine
- lysine derivatives
- Prior art date
Links
- 150000002668 lysine derivatives Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/407,899 US5843894A (en) | 1995-03-21 | 1995-03-21 | Methods for reduced renal uptake of antibody fragments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL117564A0 IL117564A0 (en) | 1996-07-23 |
| IL117564A true IL117564A (en) | 2005-03-20 |
Family
ID=23614010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11756496A IL117564A (en) | 1995-03-21 | 1996-03-20 | Pharmaceutical and diagnostic compositions containing lysine derivatives |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US5843894A (de) |
| EP (1) | EP0767673B1 (de) |
| JP (1) | JPH10505866A (de) |
| AT (1) | ATE254469T1 (de) |
| CA (1) | CA2190867C (de) |
| DE (1) | DE69630761T2 (de) |
| ES (1) | ES2211951T3 (de) |
| IL (1) | IL117564A (de) |
| WO (1) | WO1996029087A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| EP1187637A2 (de) * | 1999-06-07 | 2002-03-20 | Center For Molecular Medicine And Immunology | Alpha und beta strahlern angekoppelt zu fragmente im radioimmunotherapie |
| AU6275800A (en) * | 1999-07-16 | 2001-02-05 | Mallinckrodt, Inc. | Inhibition of renal uptake of molecules that are potentially damaging for the kidney |
| EP1862172A1 (de) * | 2006-05-31 | 2007-12-05 | BioSynthema Inc. | Zusammensetzung von einer Aminosäurelösung und Gelatine zur Hemmung renaler Aufnahme |
| WO2013106824A1 (en) * | 2012-01-13 | 2013-07-18 | Board Of Regents, The University Of Texas System | Epherin receptor targeting agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283342A (en) * | 1992-06-09 | 1994-02-01 | Neorx Corporation | Biotinylated small molecules |
| US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| US5595734A (en) * | 1988-04-06 | 1997-01-21 | Alfacell Corporation | Compositions comprising ONCONASE (tm) and lovastatin |
| ATE136224T1 (de) * | 1989-09-29 | 1996-04-15 | Neorx Corp | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten |
| US5225180A (en) * | 1991-09-10 | 1993-07-06 | Diatech, Inc. | Technetium-99m labeled somatostatin-derived peptides for imaging |
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| US5840296A (en) * | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
-
1995
- 1995-03-21 US US08/407,899 patent/US5843894A/en not_active Expired - Lifetime
-
1996
- 1996-03-20 ES ES96910422T patent/ES2211951T3/es not_active Expired - Lifetime
- 1996-03-20 IL IL11756496A patent/IL117564A/xx active IP Right Grant
- 1996-03-20 CA CA002190867A patent/CA2190867C/en not_active Expired - Fee Related
- 1996-03-20 DE DE69630761T patent/DE69630761T2/de not_active Expired - Lifetime
- 1996-03-20 AT AT96910422T patent/ATE254469T1/de not_active IP Right Cessation
- 1996-03-20 WO PCT/US1996/003308 patent/WO1996029087A1/en not_active Ceased
- 1996-03-20 JP JP8528465A patent/JPH10505866A/ja active Pending
- 1996-03-20 EP EP96910422A patent/EP0767673B1/de not_active Expired - Lifetime
-
1998
- 1998-11-30 US US09/200,791 patent/US20020111300A1/en not_active Abandoned
-
2003
- 2003-05-15 US US10/438,219 patent/US20030203836A1/en not_active Abandoned
-
2006
- 2006-01-30 US US11/341,431 patent/US20060182683A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL117564A0 (en) | 1996-07-23 |
| US20060182683A1 (en) | 2006-08-17 |
| US20020111300A1 (en) | 2002-08-15 |
| CA2190867A1 (en) | 1996-09-26 |
| ATE254469T1 (de) | 2003-12-15 |
| US20030203836A1 (en) | 2003-10-30 |
| DE69630761T2 (de) | 2004-09-23 |
| AU700346B2 (en) | 1999-01-07 |
| AU5361696A (en) | 1996-10-08 |
| EP0767673A1 (de) | 1997-04-16 |
| EP0767673B1 (de) | 2003-11-19 |
| EP0767673A4 (de) | 1999-08-04 |
| JPH10505866A (ja) | 1998-06-09 |
| DE69630761D1 (de) | 2003-12-24 |
| WO1996029087A1 (en) | 1996-09-26 |
| CA2190867C (en) | 2009-06-02 |
| ES2211951T3 (es) | 2004-07-16 |
| US5843894A (en) | 1998-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| JPH09508141A (ja) | ビタミンb▲下12▼とタンパク質との複合体 | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| BG101118A (en) | Therapeutical compounds | |
| EP0701448A4 (de) | Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren | |
| BR0112591A (pt) | Derivados de acridina e sua aplicação como medicamento | |
| NO972968D0 (no) | Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler | |
| IL87740A (en) | Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same | |
| DE69829175D1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen | |
| AR022252A1 (es) | Composicion de administracion oral. | |
| DE69230500D1 (de) | Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden. | |
| WO1992019213A3 (en) | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy | |
| BR0016339A (pt) | Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto | |
| DE69812727D1 (de) | Opioid-konjugate mit endogenen Trägerproteinen | |
| PL345959A1 (en) | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | |
| WO1999007401A3 (de) | Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen | |
| EE04606B1 (et) | H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks | |
| WO1996024370B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
| KR970025615A (ko) | 암 전이 억제제 | |
| DE69125715D1 (de) | Heterozyklische verbindungen | |
| TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
| ATE196768T1 (de) | Neue 6-hydroxy und 6-oxo-androstan verbindungen mit kardioaktivität und pharmazeutische präparate davon | |
| CA2038744A1 (en) | Pharmaceutical composition containing slightly water-soluble drug | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |